{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:04:56Z","timestamp":1761894296029,"version":"build-2065373602"},"reference-count":47,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2006,5,11]],"date-time":"2006-05-11T00:00:00Z","timestamp":1147305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The response to antifungal therapy alone often is suboptimal in patients with cancer who have therapy\u2010refractory neutropenia, and even donor\u2010derived granulocyte transfusions (GTX) are not always successful. The authors evaluated the safety and efficacy of immune enhancement using recombinant interferon \u03b31b (rIFN\u2010\u03b31b) in patients with cancer who received GTX for refractory, systemic, opportunistic infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twenty recipients of high\u2010dose donor GTX (\u22485.5 \u00d7 10<jats:sup>10<\/jats:sup> neutrophils per transfusion) who had received concurrent rIFN\u2010\u03b31b between October 2001 and December 2004 were evaluated retrospectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The median age (\u00b1 standard deviation [SD]) was 45 \u00b1 17 years. Ten patients (50%) were men, 17 patients (85%) had leukemia, and 3 patients (15%) had myelodysplastic syndrome. The median \u00b1 SD Acute Physiology and Chronic Health Evaluation II score was 15 \u00b1 4 (range, 7\u201022). Most patients (<jats:italic>n<\/jats:italic> = 18 patients; 90%) had recurrent or refractory cancer. In 6 patients (30%) who received allogeneic hematopoietic stem cell transplantation, GTX plus rIFN\u2010\u03b31b was given a median \u00b1 SD of 26 \u00b1 100 days (range, 12\u2010372 days) after transplantation. Seventeen patients (85%) had neutropenia during GTX therapy. Five patients (25%) had possible invasive fungal infection, 3 patients (15%) had probable invasive fungal infection, and 11 patients (55%) had proven invasive fungal infection. One patient (5%) had refractory <jats:italic>Pseudomonas aeruginosa<\/jats:italic> sepsis. Eight patients (40%) received corticosteroids during GTX plus rIFN\u2010\u03b31b therapy. Patients received a median \u00b1 SD of 8 \u00b1 7 GTX doses (range, 4\u201028 doses) and 9 \u00b1 7 rIFN\u2010\u03b31b doses (range, 1\u201028 doses), for a mean \u00b1 SD cumulative dose (CD) of 400 \u00b1 2621 \u03bcg. Other concomitant cytokines were granulocyte\u2010colony stimulating factor (12 \u00b1 3 doses; CD, 6720 \u00b1 4721 \u03bcg) in 15 patients (75%) and granulocyte\u2010macrophage\u2013colony stimulating factor (12 \u00b1 9 doses; CD, 4750 \u00b1 4410 \u03bcg) in 14 patients (70%). Four patients (20%) developed fever, and 2 patients (10%) developed skin rashes. Reversible liver dysfunction (<jats:italic>n<\/jats:italic> = 3 patients; 15%) and tachycardia (<jats:italic>n<\/jats:italic> = 1 patients; 5%) were considered rIFN\u2010\u03b31b\u2010associated adverse reactions; whereas, in 1 patient (5%), transient dyspnea was attributed to GTX. Four weeks after therapy started, 9 patients (45%) had complete or partial resolution of infection; and, in another 3 patients (15%), the invasive fungal infection had become stable.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The current results indicated that no serious adverse events were associated with rIFN\u2010\u03b31b immune enhancement in patients with systemic opportunistic infections who received donor GTX therapy. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21929","type":"journal-article","created":{"date-parts":[[2006,5,12]],"date-time":"2006-05-12T03:03:36Z","timestamp":1147403016000},"page":"2664-2671","source":"Crossref","is-referenced-by-count":64,"title":["Recombinant interferon \u03b31b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions"],"prefix":"10.1002","volume":"106","author":[{"given":"Amar","family":"Safdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilhen H.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Lichtiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burton F.","family":"Dickey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil J.","family":"Freireich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam I.","family":"Raad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,5,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20710"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402007"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/14653240310000047"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1055-z"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0439-6"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04583.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400811"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.749"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-3-199508010-00009"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00227.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/10799900152547821"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/422993"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01313-X"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-6-200303180-00030"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301904"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.57.4.651"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.61.11.4870-4877.1993"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20883"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01849.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4049\/jimmunol.138.3.765","article-title":"Immune interferon enhances properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte\u2010macrophage colony\u2010stimulating factor","volume":"138","author":"Perussia B","year":"1987","journal-title":"J Immunol."},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.4049\/jimmunol.135.3.2069","article-title":"Activation of human polymorphonuclear neutrophil functions by interferon\u2010gamma and tumor necrosis factor","volume":"135","author":"Shalaby MR","year":"1985","journal-title":"J Immunol."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1309\/EXBVYAUPENBM285Y"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2129-2133.2001"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.4.501"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood.V88.11.4383.4383","article-title":"Tacrolimus and mini\u2010dose methotrexate for prevention of acute graft\u2010versus\u2010host disease after matched unrelated donor marrow transplantation","volume":"88","author":"Przepiorka D","year":"1996","journal-title":"Blood."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70042-5"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1964.tb40726.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.7.1675.1675"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/323335"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703252"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000091182.93122.8e"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/1-4020-8010-7_7"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/502104"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/342568"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198510000-00009"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-64-2-328"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309064277"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01619.x"},{"key":"e_1_2_5_40_2","first-page":"1516","article-title":"Separation and collection of leukocytes","volume":"25","author":"Freireich EJ","year":"1965","journal-title":"Cancer Res."},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1997)12:2<74::AID-JCA4>3.0.CO;2-6"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14904-5"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1086\/340221"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3801-3805.2004"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/368383"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0456"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1496"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/423380"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21929","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:46:02Z","timestamp":1760269562000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,11]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,6,15]]}},"alternative-id":["10.1002\/cncr.21929"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21929","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2006,5,11]]}}}